TABLE 2.
Summary of effectiveness of compounds against HuNoV in HIEs a
| Figure | Genotype | P-type | HIE line | Compound | EC90 (μM) | EC50 (μM) | CC50 (μM) | SI | Antiviral activity |
|---|---|---|---|---|---|---|---|---|---|
| 2 | GII.4 Sydney | GII.P31 | J2 | 2′CMC | 54.0 | 10.0 | >316 | >31.6 | At least moderate |
| 3 | GII.4 Sydney | GII.P31 | J2 | NTZ | 43.0 | 37.1 | 69.7 | 1.9 | Inactive |
| 4 | GII.3 | GII.P21 | J4FUT2 | NTZ | >80 | 14.4 | 64.7 | 4.5 | Weak |
| 5 | GII.17 | GII.P13 | J4FUT2 | NTZ | >80 | 33.4 | 63.6 | 1.9 | Inactive |
| 6 | GI.1 | GI.P1 | J4FUT2 | NTZ | 76.3 | 27.4 | 73.3 | 2.7 | Weak |
| 7 | GII.4 Sydney | GII.P16 | J2 | NTZ | >80 | 12.9 | 51.2 | 4.0 | Weak |
| 7 | GII.4 Sydney | GII.P16 | D2004 | NTZ | >80 | 42.8 | 50.9 | 1.2 | Inactive |
| 7 | GII.4 Sydney | GII.P16 | J2004 | NTZ | >80 | 53.9 | 63.1 | 1.2 | Inactive |
| 7 | GII.4 Sydney | GII.P16 | IL2004 | NTZ | 46.0 | 40.0 | 57.0 | 1.4 | Inactive |
a
EC50 and EC90 were calculated on the percent inhibition data, and CC50 was calculated on the percent viability data presented in Fig. 2 to 7 using non-linear regression. Selective index (SI) was calculated using EC50 and CC50. Antiviral activity of each compound is denoted based on the SI: inactive = SI < 2; weak = 2 ≤ SI < 10; moderate = 10 ≤ SI < 50; high = SI ≥ 50.